{
}
XTX Topco Ltd increased its stake in NeuroPace, Inc., now holding 24,055 shares valued at $182,000. NeuroPace, which develops a brain-responsive neuromodulation system for epilepsy treatment, has a "Moderate Buy" rating from analysts, with a consensus target price of $15.33. The company reported a revenue of $21.06 million for the last quarter, surpassing estimates, while institutional investors own 78.83% of the stock.
UBS has initiated coverage on NeuroPace Inc., assigning a Buy rating and a price target of $17.00, citing strong growth potential driven by its unique RNS technology for drug-resistant epilepsy. The company reported a record third-quarter revenue of $21.1 million, a 28% increase year-over-year, and anticipates a revenue range of $78 million to $80 million for 2024. With a projected 22% CAGR from 2024 to 2029, NeuroPace is positioned for significant market expansion, particularly with catalysts expected in late 2025.
UBS has initiated coverage on NeuroPace Inc, assigning a Buy rating with a price target of $17.00, citing strong growth potential driven by its unique RNS technology for drug-resistant epilepsy. The company reported a record $21.1 million in Q3 revenue, a 28% increase year-over-year, and anticipates a revenue range of $78 million to $80 million for 2024. With a projected 22% CAGR from 2024 to 2029, NeuroPace is positioned for significant market expansion, particularly in the second half of 2025.
NeuroPace, Inc.
Companies
| Symbol | NPCE |
| Name | NeuroPace, Inc. |
| Currency | USD |
| Sector | Health Care |
| IndustryGroup | Health Care Equipment & Services |
| Industry | Health Care Technology |
| Market | NASDAQ Global Select |
| Country | United States |
| State | CA |
| City | Mountain View |
| Zipcode | 94043 |
| Website | http://www.neuropace.com |
The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
neuropace reports earnings beat and receives buy rating from UBS Group
14:30 21.01.2025
ubs initiates coverage on neuropace with strong growth outlook and buy rating
11:51 21.01.2025
ubs initiates coverage on neuropace with strong growth outlook and buy rating
11:40 21.01.2025
Trending
Subcategory
Industry Trends
Corporate News
Supply Chain Management
Startups & Entrepreneurship
Global Trade Developments
Government Economic Policies
Industry Mergers & Acquisitions
Retail and Consumer Goods
Finance Mergers & Acquisitions
Financial Scams and Security
Fintech Startups
Emerging Startups
Workplace Trends
Venture Capital Investments
Cryptocurrency Trends
Funding Rounds & Investments
Energy Sector Developments
CEO Changes
Market Analysis and Predictions
Stock Market Updates
Countries:
Companies:
Apple Inc.
Google Inc.
NVIDIA Corporation
Delhivery Limited
Ecom Express Ltd.
Alphabet Inc.
OpenAI ERC USD
Ciscom Corp.
ERICSSON - CLASS B
Physicswallah Ltd.
Learning Resources Inc.
MGA Entertainment Inc.
State Street Global Advisors Luxembourg SICAV - SSGA EMU ESG Screened Equity Fund
Snap Inc.
Tiktok USD
Semiconductor Manufacturing International Corporation
Hua Hong Semiconductor Ltd.
Spotify Technology S.A.
Dropbox, Inc.
Vimeo, Inc.
Currencies:
United States Dollar
Indian Rupee
Chinese Yuan
Euro
Vietnamese Đồng
New Taiwan Dollar
United Arab Emirates Dirham
Russian Ruble
South Korean Won
Pakistani Rupee
Algerian Dinar
Australian Dollar
Thai Baht
Japanese Yen
Saudi Riyal
People:
Donald Trump
Ilya Sutskever
Peter Thiel
Amal El Fallah Seghrouchni
Trixie Lohmirmand
Scott Bessent
Jamieson Greer
Joe Jurken
Stephen Roachford
David French
Rick Woldenberg
Marc Rosenberg
Isaac Larian
Hichem Djouhri
Laurina Emmanuel
Tim Cook
Andrew Ferguson
Sheryl Sandberg
Mark Zuckerberg
Pavel Prass